Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

MicroRNA-200c promotes tumor cell proliferation and migration by directly targeting dachshund family transcription factor 1 by the Wnt/β-catenin signaling pathway in nasopharyngeal carcinoma

Cao, Weia,b; Sun, Jingwua

doi: 10.1097/CAD.0000000000000713
PRECLINICAL REPORTS
Buy

The purpose of the present study was to determine the crucial role of microRNAs (miRNAs/miRs) involved in the proliferation and migration of nasopharyngeal carcinoma (NPC) and to investigate their underlying mechanisms. In this study, we focused on the expression and function of miR-200c in NPC. First, we found the expression level of miR-200c in NPC cells and tissues was upregulated, and it was suggested that the high expression of miR-200c accelerated the proliferation and migration of NPC cells in vitro. Notably, a result of the present study was that the cell fate determination factor dachshund family transcription factor 1 (DACH1) was identified as a direct target of miR-200c. Suppression of miR-200c expression in NPC cells increased endogenous DACH1 mRNA and protein levels, which was negatively correlated with miR-200c. Meanwhile, DACH1 was shown to regulate the Wnt/β-catenin signaling pathway. Accordingly, it was concluded that miR-200c exerted a tumor-promoting role in NPC development by targeting DACH1, which may contribute to the increase in the rates of NPC proliferation and migration. miR-200c may be a potential diagnostic and prognostic biomarker for NPC.

aDepartment Otorhinolaryngology, Head and Neck Surgery, The Anhui Provincial Hospital of Anhui Medical University

bDepartment of Otorhinolaryngology, Head and Neck Surgery, The Second Hospital of Anhui Medical University, Hefei, China

Correspondence to Jingwu Sun, MSc, Department Otorhinolaryngology, Head and Neck Surgery, The Anhui Provincial Hospital of Anhui Medical University, Hefei 230001, China Tel: +86 551 6228 3114; fax: +86 551 228 3409; e-mail: sunjw69@126.com

Received August 20, 2018

Accepted October 19, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.